Genomma Lab Internacional Stock EBITDA
Genomma Lab Internacional fundamentals help investors to digest information that contributes to Genomma Lab's financial success or failures. It also enables traders to predict the movement of Genomma Pink Sheet. The fundamental analysis module provides a way to measure Genomma Lab's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genomma Lab pink sheet.
Genomma |
Genomma Lab Internacional Company EBITDA Analysis
Genomma Lab's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Genomma Lab EBITDA | 2.84 B |
Most of Genomma Lab's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genomma Lab Internacional is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Genomma Lab Internacional reported earnings before interest,tax, depreciation and amortization of 2.84 B. This is 223.28% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all United States stocks is 27.24% higher than that of the company.
Genomma EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genomma Lab's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genomma Lab could also be used in its relative valuation, which is a method of valuing Genomma Lab by comparing valuation metrics of similar companies.Genomma Lab is currently under evaluation in ebitda category among its peers.
Genomma Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.09 B | |||
| Shares Outstanding | 1 B | |||
| Shares Owned By Insiders | 29.00 % | |||
| Shares Owned By Institutions | 29.10 % | |||
| Price To Earning | 11.09 X | |||
| Price To Book | 1.38 X | |||
| Price To Sales | 0.05 X | |||
| Revenue | 15.49 B | |||
| Gross Profit | 9.56 B | |||
| EBITDA | 2.84 B | |||
| Net Income | 1.31 B | |||
| Cash And Equivalents | 1.3 B | |||
| Cash Per Share | 1.30 X | |||
| Total Debt | 3.83 B | |||
| Debt To Equity | 0.51 % | |||
| Current Ratio | 1.67 X | |||
| Book Value Per Share | 10.98 X | |||
| Cash Flow From Operations | 1.47 B | |||
| Earnings Per Share | 0.07 X | |||
| Number Of Employees | 2.3 K | |||
| Beta | 0.53 | |||
| Market Capitalization | 973.77 M | |||
| Total Asset | 21.54 B | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 21.54 B | |||
| Last Dividend Paid | 0.38 |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Genomma Pink Sheet
If you are still planning to invest in Genomma Lab Internacional check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genomma Lab's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |